Review
Immunology
Martin Aringer, Karen Costenbader, Sindhu R. Johnson
Summary: External validation worldwide has confirmed the concepts and performance of the new EULAR/ACR SLE classification criteria. However, variation in specificity may be due to incomplete application of the attribution rule, while uncertainty and lack of consensus on disease entity boundaries also contribute to variation in estimates. Sensitivity relies heavily on the performance of ANA tests.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2022)
Article
Engineering, Environmental
Ting Liu, Xi Zhang, Lizhen He, Zehang Zhang, Yuhan Sun, Junmei Feng, Zhiming Lin, Tianfeng Chen
Summary: This study developed a selenium nanosystem with surface decoration of calf thymus DNA to specifically recognize and remove anti-dsDNA autoantibodies in SLE patients. The nanotherapeutics showed excellent biocompatibility and safety, and had higher clearance ratio compared to other clinical products. Furthermore, the nanotherapeutics could visualize the distribution of anti-dsDNA antibodies in kidney lesions and semi-quantify the antibody deposition.
CHEMICAL ENGINEERING JOURNAL
(2022)
Article
Rheumatology
Chanidapa Wongtada, Stephen J. Kerr, Pawinee Rerknimitr
Summary: The lupus band test performed on non-lesion skin can be valuable for diagnosing systemic lupus erythematosus, especially in cases with insufficient clinical and serological profiles.
Article
Biochemistry & Molecular Biology
Tatiana Reshetnyak, Fariza Cheldieva, Maria Cherkasova, Alexander Lila, Evgeny Nasonov
Summary: This study investigates the role of IgA antibodies to cardiolipin (aCL) and IgA antibodies to beta-2 glycoprotein 1 (anti-beta(2)-GP1) in the development of vascular complications in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The results show that the levels of IgA aCL and IgA anti-beta(2)-GP1 are significantly higher in APS patients compared to SLE patients and the control group. These antibodies are closely associated with thrombosis in APS, demonstrating high specificity but low sensitivity for the diagnosis of APS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
Maurizio Bruschi, Gabriella Moroni, Renato Alberto Sinico, Franco Franceschini, Micaela Fredi, Augusto Vaglio, Lorenzo Cavagna, Andrea Petretto, Federico Pratesi, Paola Migliorini, Francesco Locatelli, Giulia Pazzola, Giampaola Pesce, Marcello Bagnasco, Angelo Manfredi, Giuseppe A. Ramirez, Pasquale Esposito, Giuseppe Murdaca, Simone Negrini, Leda Cipriani, Barbara Trezzi, Giacomo Emmi, Ilaria Cavazzana, Valentina Binda, Matteo d'Alessandro, Paride Fenaroli, Isabella Pisani, Giacomo Garibotto, Carlomaurizio Montecucco, Domenico Santoro, Francesco Scolari, Stefano Volpi, Marta Mosca, Angela Tincani, Giovanni Candiano, Marco Prunotto, Enrico Verrina, Andrea Angeletti, Angelo Ravelli, Gian Marco Ghiggeri
Summary: The circulating anti-ENO1, anti-H2A, and anti-ANXA1 antibodies were associated with high proteinuria in lupus nephritis patients, with the anti-ENO1 antibody showing the maximum reduction within 12 months paralleling the decrease in proteinuria. Anti-dsDNA antibodies were not linked to renal outcome parameters. New IgG2 antibody signatures have the potential to be used as markers for personalized therapies in lupus nephritis.
Article
Rheumatology
Robin Arcani, Daniel Bertin, Nathalie Bardin, Karin Mazodier, Rodolphe Jean, Pierre Suchon, Geoffroy Venton, Aurelie Daumas, Estelle Jean, Patrick Villani, Gilles Kaplanski, Pierre-Andre Jarrot
Summary: The study shows that anti-NuMA antibodies are mainly associated with pSS and SLE, and patients with these antibodies have less severe clinical profiles and require less treatment. Anti-NuMA antibodies may be a useful diagnostic marker when other auto-antibodies are negative and could indicate a good prognosis in autoimmune diseases.
Review
Immunology
Aleida Susana Castellanos Gutierrez, Francesc Figueras, Diana M. Morales-Prieto, Ekkehard Schleussner, Gerard Espinosa, Nuria Banos
Summary: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects women of childbearing age. During pregnancy, SLE is associated with a higher risk of perinatal morbidity and mortality. Several studies have suggested that placental dysfunction may play a crucial role in this association.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tatiana Reshetnyak, Kamila Nurbaeva, Ivan Ptashnik, Anna Kudriaeva, Alexey Belogurov Jr, Aleksandr Lila, Evgeny Nasonov
Summary: This study aimed to assess the role of neutrophil extracellular traps (NETs) markers, MPO-DNA complex and nucleosomes, in the diagnosis of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The study found that levels of MPO-DNA complex were higher in SLE patients and associated with SLE activity and lupus glomerulonephritis. Lower levels of nucleosomes were observed in SLE patients and associated with SLE activity and arthritis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Rheumatology
Jiawei Zhao, Xin You, Xiaofeng Zeng
Summary: This article reviews the prevalence and pathogenesis of BKV infection in SLE patients. The results show higher rates of BKV infection and reactivation in SLE patients, and some immunosuppressive drugs may have a protective effect. BKV infection plays a role in the occurrence and development of SLE.
Article
Medicine, General & Internal
Eric F. Morand, Edward M. Vital, Michelle Petri, Ronald van Vollenhoven, Daniel J. Wallace, Marta Mosca, Richard A. Furie, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Bochao Jia, Brenda Crowe, Inmaculada de la Torre, Thomas Doerner
Summary: The objective of this study was to evaluate the efficacy and safety of baricitinib in patients with active SLE. The results showed that baricitinib 4 mg significantly improved SLE disease activity compared with placebo, but key secondary endpoints were not met. The safety profile of baricitinib in patients with SLE was consistent with the known safety profile.
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Yanli Zeng, Yun Xiao, Fanxiang Zeng, Longcan Jiang, Shuidi Yan, Xuelian Wang, Qiaoduan Lin, Liang Yu, Xinxin Lu, Yan Zhang, Yiqiang Lin
Summary: This study aimed to investigate the levels of anti-nucleosome antibody (ANuA) isotypes in patients with systemic lupus erythematosus (SLE) and identify ANuA isotypes that can diagnose and predict SLE. The levels of three ANuA isotypes (IgG, IgA, and IgM) were significantly higher in SLE patients compared to patients with other autoimmune diseases and healthy controls. Furthermore, the levels of ANuA isotypes were positively correlated with SLE disease activity, high-avidity IgG ANAs, and serum anti-dsDNA IgG levels. ANuA isotypes showed high sensitivity and specificity for the diagnosis of SLE and lupus nephritis.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Tao Ming Sim, Siying Jane Ong, Anselm Mak, Sen Hee Tay
Summary: This review discusses the bench to bedside translation of the type I IFN pathway and explores some unresolved issues when selecting SLE patients for treatment with biologics targeting type I IFNs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Jamil A. Al-Mughales
Summary: This study aimed to explore the pathogenic significance of ANA patterns in SLE patients. The speckled and homogeneous patterns were found to be the most common, and they were associated with other immune markers. Peripheral, mixed, and speckled patterns showed higher levels of immune markers, indicating a potential prognostic value in SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Hiro Ueda, Nehal E. Elsadek, Hidenori Ando, Yu Ishima, Tatsuhiro Ishida
Summary: Research shows that nucleic acids associated with PEGylated cationic liposomes induce anti-DNA or anti-RNA antibodies in healthy mice, but do not cause SLE-like symptoms. However, in mice with SLE, nucleic acids associated with PCL exacerbate lupus nephritis symptoms.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)